Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | PLAU | P00749 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | PLAT | P00750 | 1/20 | 0.59 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.59 |
| ▸ | KLK1 | P06870 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7852367 | 0.92 | GRM5 (0.54) | GRM5NPC1PLAUF2PLG | |
| SCHEMBL9963860 | 0.90 | GRM5 (0.75) | GRM5NPC1RAB9APKM | |
| SCHEMBL13296220 | 0.81 | GRM5 (0.82) | GRM5NPC1RAB9APKM | |
| SCHEMBL2947068 | 0.80 | GRM5 (0.68) | GRM5NPC1RAB9APKM | |
| SCHEMBL7340325 | 0.79 | GRM5 (0.56) | GRM5NPC1RAB9APKM | |
| SCHEMBL7341806 | 0.79 | SIRT2 (0.59) | PLAUF2PLGPLATKLKB1 | |
| SCHEMBL7406442 | 0.79 | NPC1 (0.63) | NPC1PLAUF2PLGPLAT | |
| SCHEMBL7334311 | 0.78 | KDM4E (0.58) | NPC1PLAUF2PLGPLAT | |
| SCHEMBL8557860 | 0.77 | GRM5 (1.00) | GRM5NPC1RAB9A | |
| SCHEMBL10806526 | 0.77 | GRM5 (0.68) | GRM5NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | GRM5 4207/4885NPC1 2478/4885PLAU 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.